Aim 3, Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care

Sponsor
Rutgers, The State University of New Jersey (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05400941
Collaborator
National Cancer Institute (NCI) (NIH)
910
1
2
24
37.9

Study Details

Study Description

Brief Summary

This mixed methods study evaluates the effectiveness of an organizational intervention to enhance implementation of strategies to increase breast cancer survivorship symptom and risk management.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Practice Led Intervention
N/A

Detailed Description

Aim 3 is a hybrid type 1 effectiveness-implementation cluster randomized study with a waitlist control in 26 primary care practices. This study uses a tailored combination of practice facilitation, expert consultation, collaborative learning events, and audit and feedback as intervention strategies, and a mixed-methods comparative case study learning evaluation for primary care practices to adapt priority recommendations of evidence-based activities for breast cancer survivorship care. Intervention effectiveness will be assessed in two groups of clinics: 13 cases that will receive the implementation intervention and 13 waitlist controls. Impact of this implementation will be measured using mixed methods to assess Exploration, Preparation, Implementation and Sustainment factors related to how organizational and contextual variables affect adoption, implementation and early sustainability for provision of follow-up care, symptom, and risk management activities at 6 and 12 months post implementation. Aim 3 surveys 20 clinicians and staff members from 26 intervention practices (n=520) and conducts key informant interviews with 5 health care team members (who have participated in the survey; n=130) and 15 breast cancer survivors per practice (n=390; 5 per assessment point at baseline, 6 months and 12 months post intervention). Medical records of 20 patients with a history of breast cancer per practice per assessment point at baseline, 6 months and 12 months post intervention will be randomly selected for review (N=1,560) to assess and compare comprehensive breast cancer follow-up care outcomes. Sustainment will be measured through continued monitoring of the medical records for the 13 initial intervention practices at 18 and 24 months (N=520).

Study Design

Study Type:
Interventional
Anticipated Enrollment :
910 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Health Services Research
Official Title:
Adapting and Implementing Evidence-based Breast Cancer Follow-up in Primary Care
Anticipated Study Start Date :
Dec 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2025
Anticipated Study Completion Date :
Dec 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Practice Led Intervention

Clinic staff will participate in learning collaborative and practice facilitation as well as receive expert consultation and audit and feedback.

Behavioral: Practice Led Intervention
This is a quality improvement intervention that includes learning collaboratives, practice facilitation, expert consultation and audit and feedback.

No Intervention: Standard of Care

No intervention.

Outcome Measures

Primary Outcome Measures

  1. Change in Comprehensive Breast Cancer Follow-up Care [Repeated measures at baseline, 6 months, 12 months, 18 months and 24 months]

    Percent of eligible recommendations performed per patient to assess the comprehensiveness of the follow up care received

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Self-identification as a staff member or patient who has had breast cancer in a participating practice
Exclusion Criteria:
  • Unable to speak, understand and/or read English

  • Unable to provide informed consent

Contacts and Locations

Locations

Site City State Country Postal Code
1 Rutgers University New Brunswick New Jersey United States 08901

Sponsors and Collaborators

  • Rutgers, The State University of New Jersey
  • National Cancer Institute (NCI)

Investigators

  • Principal Investigator: Shawna V Hudson, PhD, Rutgers University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Shawna V. Hudson, PhD, Professor, Rutgers, The State University of New Jersey
ClinicalTrials.gov Identifier:
NCT05400941
Other Study ID Numbers:
  • Pro2021000838
  • R01CA257197
First Posted:
Jun 2, 2022
Last Update Posted:
Jun 2, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 2, 2022